September is Blood Cancer Awareness Month. We stand with everyone living with blood cancer — this month and every day.

Lower-risk Myelodysplastic Syndromes (LR-MDS)

Living with LR-MDS is about more than blood counts.
For many people living with lower-risk myelodysplastic syndromes (LR-MDS), the impact of disease is often felt long before it shows up on a lab report. Despite its name, ‘lower-risk’ does not mean the disease is less serious. LR-MDS symptoms can make everyday activities more challenging. In addition, living with LR-MDS requires ongoing disease management. Understanding LR-MDS is an important first step toward managing care and finding support.

understanding the disease

What is LR-MDS?

Lower-risk myelodysplastic syndromes (LR-MDS) is one form of myelodysplastic syndromes (MDS), a group of rare blood cancers that begin in the bone marrow. Bone marrow is the soft, spongy tissue inside the bones where many kinds of blood cells are made. In people with MDS, the bone marrow does not produce healthy blood cells effectively, resulting in lower numbers of red blood cells, white blood cells, and/or platelets. LR-MDS is the most common form of MDS, affecting about 7 in 10 people who are diagnosed with MDS.

We can add this here to help explain LRD-MDS: “There are several types of MDS. In some cases, MDS can progress to acute myeloid leukemia (AML). When AML is less likely to develop, healthcare providers will refer to the condition as lower-risk MDS (LR-MDS).LR-MDS occurs most often in older adults. On average, most people are diagnosed later in life, usually in their 70s. It is more common in men than women.

3d rendered medically accurate illustration of too many white blood cells due to leukemia

beyond the diagnosis

The reality of living with LR-MDS

The disease burden

MDS is a progressive disease, which means it may change or get worse over time. In its early stages, there may be few or no symptoms. For some people, low blood cell counts revealed through a routine blood test may be the first sign. However, symptoms may change as the disease progresses. The impact of LR-MDS is felt in everyday life and affects a person's sense of independence.

lrmds female patient experiencing symptoms, sitting on staircase in home

Symptoms that shape everyday life

The treatment burden

Managing LR-MDS often involves more than treating symptoms. Regular appointments, blood tests, monitoring, and blood transfusions can become a part of daily life, affecting routines, work, family, responsibilities, and future plans.

LR-MDS patient receiving treatment in hospital with caretaker and healthcare worker

How treatment management affects daily life

living with LR-MDS

Voices from the community

"Living with lower-risk myelodysplastic syndrome is a trip that you wish you didn't have to take. Sometimes I feel like I can't possibly do normal things – like grocery shopping, tidying up the house or even walking to the door to hang a holiday wreath. I just am so persistently and relentlessly tired. It feels like trying to walk through cement."

— Linda

Living with LR-MDS

beyond symptom management

A different way of treating LR-MDS

For many years, treatment for LR-MDS has focused primarily on managing effects of the disease. Geron's approach is different. It targets telomerase, an enzyme that many cancer cells depend on to continue growing and dividing, with the goal of addressing an underlying disease mechanism.

  • checkmark icon

    What is telomerase?

    Telomerase is an enzyme that helps certain cells continue to divide. Most healthy cells have little or no telomerase activity, but many cancer cells depend on it to keep growing. Because of this, telomerase has become an important focus of research in blood cancers such as LR-MDS.

  • checkmark icon

    How is this different from other approaches?

    Many treatments for LR-MDS focus on managing the effects of the disease. For example, blood transfusions temporarily replenish red blood cells to help relieve symptoms of anemia. Telomerase inhibition works differently. By limiting telomerase activity, cancer cells gradually begin to die, creating the potential for healthy blood-forming cells to recover in the bone marrow.

telomerase blocked

beyond the medicines

How we are supporting the LR-MDS community

Our commitment to the LR-MDS community extends beyond science and medicine. Through education, advocacy partnerships, and awareness efforts, we strive to help people impacted by LR-MDS feel informed, supported, and connected.

  • checkmark icon navy

    Partnerships with Patient and Professional Advocacy Organizations

    We work alongside patient and professional advocacy organizations that provide trusted information, practical resources, and a sense of community for people impacted by blood cancers such as LR-MDS. Together, we aim to help ensure patients and care partners have access to the support they need through their journey.

    Learn more about partnering
  • checkmark icon navy

    Educational resources

    An LR-MDS diagnosis often comes with uncertainty. We support educational programs and resources that help patients, care partners, and healthcare professionals better understand the disease, navigate treatment conversations, and feel more informed throughout their care journey.

    Explore educational resources
  • checkmark icon navy

    Supporting awareness

    Because LR-MDS is a rare blood cancer, awareness remains limited, and misconceptions about the disease persist. We support efforts to increase recognition and understanding, encourage earlier conversations, and connect more people with trusted information and resources.

    Connect with advocacy organizations

find more information

Additional resources

Whether you're newly diagnosed, supporting a loved one, or looking to learn more about LR-MDS, these resources can help you better understand the disease, find support, and stay informed about ongoing research.